InvoBioscience (OTC:IVOB) is engaged in providing its InvoCell technology to help infertile couples have a baby. It has one principal product, the manufacturing and distribution of the InvoCell technology.

@@CalendarRight@@ InvoBioscience has rapidly conquered many countries with a big market potential. Distributor contracts have been signed all over the world; registration process for clearance when it is needed has been started as well. Their strategy to focus on other countries first rather than the classic USA FDA path was very well done. InvoBioscience’s incomes have started to growth on each part of the world.

While InvoBioscience has many distribution agreements coming up or already signed for many countries, this article focuses here only on the biggest markets potential.

Chinese Market

Couples in China, the world’s most populous nation, are having difficulty conceiving. Infertility in the country has risen from 12.5 to 15 percent but that number could climb quickly to about 20, according to a report released recently at a forum in Beijing.

However the price tags are prohibitive for most people – worth several or many times their annual salary – but an increasing number of Chinese families are now able to afford the treatment.

“Actually more than 10 million Chinese families need artificial fertilization”, according to Xinhua news agency.

Professor Lu Bodong, vice president of the Second Hospital of Zhenjiang Chinese Medical University in Hangzhou, east China’s Zhejiang Province, attributes rising infertility rates to stressful and unhealthy lifestyles that include excessive drinking and smoking, over-indulgence, and also environmental problems, all of which are side effects of China’s dramatic social and economic changes.

“Now, more and more people are becoming open to fertility treatment. There are more than 200 reproduction centers in China, but this is not enough to meet the demand.”

“The industry is believed to be huge in China.” says Zhao Lixin, deputy director of the reproduction center in east China’s Shandong Province Hospital.

InvoBioscience has signed a distributor contract with The Progressive Group; they are one of the larger med device and equipment distributors in this area. The registration process has been started with Chinese FDA authorities; INVO is waiting to know if a trial will need to be done in China or if the FDA will look to the European guidelines of acceptance and grade InvoCell as a Class II med device.

Indian Market

India has a population of 1.15 Billion people with an estimated 14 million infertile couples. India has power infrastructure issues throughout most of the country therefore traditional IVF is not widely available and unreliable to support. InvoCell’s lack of reliance on electric power will make infertility treatment an option that most of the population does not currently have.

India does NOT need any sort of regulatory clearance.

InvoBioscience is working with potential distributors and has trained and most likely continue to train doctors in India over the next few months.

@@AdsenseRight@@ Advaxis is using Listeria monocytogenes bacteria as a vector to destroy solid tumors in patients. There is no other biotech company that is using this modality to treat cancer patients. It is not some newly discovered drug, but based on a biological entity that has been studied for over a hundred years and whose actions have been well documented if not totally understood. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. The leading Advaxis Listeria vaccine candidate, Lovaxin C, targets cervical cancer, head cancer and neck cancers. Other Listeria vaccines in development target breast cancer, ovarian cancer and lung cancers.

Advaxis is developing multiple platform approaches to the treatment of several cancers which represent a market potential in excess of $10 billion.

Advaxis’ Phase I/II clinical cervix cancer study in their lead candidate ADXS11-001 showed an impressive overall survival rate of 53% in those patients who fail first line cytotoxic therapy (current survival rate is 5% at one year).

According to statistics provided by the GOG* (Gynaecologic Oncology Group); the median survival rate in months is increased by 88% to 200%. In addition, 3 of the 13 evaluable patients have now survived more than 3 YEARS. That is remarkable; other cancer vaccines have nowhere near the potential that the Advaxis’ vaccine platform has so far.

@@CalendarLeft@@ It is important to understand that Advaxis is developing vaccines for treating patients who have already contracted the target disease, such as cervical or breast cancer. In animal models of breast cancer, the data show that the Advaxis Lovaxin B vaccine, composed of the Listeria with the Her2/neu antigen, was able to successfully stop tumor growth.

Dr. John Rothman, Vice President of Clinical Development for Advaxis said, “The GOG* is an extremely competent and experienced group of clinical researchers. Their interest in collaborating with Advaxis is very encouraging. The GOG* has a thirty-year history of facilitating the development of many therapeutic agents that were once novel and today are well accepted as effective drugs. Our collaboration with this excellent research group will enable us to objectively demonstrate the therapeutic efficacy of our Lovaxin C vaccine for the treatment of women with cervical cancer. ”

Based on over a decade of work in the laboratory of Dr. Yvonne Paterson at the University of Pennsylvania, the Company’s broadly enabling Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Listeria has the ability to generate a robust immune response and produce an unusually strong and effective therapeutic immune response to existing cancers and other diseases affecting many related immune mechanisms simultaneously and in an integrated fashion. Advaxis’ Listeria-based technology not only generates an unusually profound cytotoxic immune response capable of killing cancer cells, but the Company’s proprietary antigen fusion protein technology minimizes the suppressive effects of regulatory T cells that appear to inhibit many vaccines, and also creates a local tumor environment conducive to the therapeutic effects of the activated tumor killing cells.

To read the previous company profile published by TheMarketFinancial, visit this link: http://www.themarketfinancial.com/holiday-season-may-bring-renewed-interest-in-bizauctions-otcbzcn-pk

About BizAuctions Inc.

@@AdsenseRight@@ Bisections Inc. is a provider of commercial eBay liquidation services for excess inventory, overstock items, and returns for retailers, manufacturers, and distributors. The Company sells from home goods, brand name clothes and electronics. The Company lists the merchandise through software which is integrated and compliant with eBay. Once an auction ends, payment is collected via PayPal or credit card. The Company is providing liquidation services to retailers in California, Arizona, and Colorado, and is in the process of expanding into other states.

Technical Chart Analysis

( Click to Enlarge )

From the chart and technical perspective, it is easy to see why an investment in BZCN would be a smart choice for potential onlookers. The stock seems to have found strong support during mid October and November at $0.0010, while a strong resistance is equally as evident within the $0.002, and $0.0025 price per share, where if broken, could see the stock rise to $0.003. The RSI (Relative Strength Index) has been consolidating around the 49.23 level and seems to be trending upwards, meaning the stock’s float is still highly oversold. The empty Doji cross which happened, also represents indecision, and perhaps a reversal from the recent bearish trend, and into a bullish trend. MACD divergence has been negative the past week, and looking at the pattern from November 23rd to December 7th (positive divergence), and as well from December 7th (and onward) the negative divergence seems to be coming to an end, which would verify the stock’s new bullish trend. Should the company release the much anticipated news, the high volume should propell the golden cross to form (50 day MA and 200 day MA) thus potentially sending the price per share to the 0.003 resistance and perhaps even higher.

Disclosure: Long BZCN

By reading TheMarketFinacial company profiles you agree to the disclaimer, and thereby will not hold the staff and authors accountable for any transactions or decisions you make. It is up to you to do your own due diligence.

TheMarketFinancial is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

Miv Investments Inc. has also confirmed a conference call with CEO, Curt Thornton, which is tentative for either 12/8/09, or 12/9/09 where a number of issues that have been raised by both institutional and private investors will be undertaken and answered. Questions may involving the following topics: debt-to-equity, revenue models, expected partnerships and deals, potential expos, gathered market data and effectiveness, competitor analysis to name a few. There are currently no financial news portals or promoters that MiV is aware of covering the company, therefore the potential could be extremely favourable given that external players foresee the short-term and long-term benefits. Provision looks set to begin generating revenues, ink partnerships and break new ground within the advertising industry throughout 2010.

About Provision Interactive Technologies Inc.

Provision Interactive Technologies, Inc. (“Provision”) develops 3D interactive display technologies for a wide array of market channels. The futuristic nature of Provision has created several early commercial applications. The Company’s initial line of display systems has proven to be ideally suited for indoor and outdoor point-of-sale, merchandising and point of sale related advertising venues. Provision is currently the market leader in true 3D consumer advertising display products being implemented by leading consumer focused Fortune 1000 companies. The interactive display technologies deliver images that engage and inform customers at point of sale and in-store advertising locations in a dramatic and persuasive manner, thereby influencing customers in their purchase-making decisions.

@@CalendarRight@@ CytRx President and CEO Steven A. Kriegsman said, “This planned clinical trial is a key step forward in our plans to build a commercial oncology franchise for CytRx. We have studied the oncology market in solid tumors and believe that stomach cancer represents a major market and an unmet medical problem worldwide. We have also been encouraged by exciting animal data for INNO-206 in a broad array of cancer indications, and are hopeful that this carefully-designed study will bring hope to the sufferers of advanced gastric cancer.”

Rumours are also swirling that a biopharma news-portal contacted the company, and news is pending on what could be a turning point for shareholders. An announcement could come as early as this week, many investors have long been awaiting news on the Tamibarotene, Acute Promyelocytic Leukemia pivotal phase II trial.

About CytRx Corporation

@@AdsenseLeft@@ CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the treatment of acute promyelocytic leukemia (APL). In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 36% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit www.cytrx.com.

Product Pipeline

CytRx Corporation’s oncology pipeline includes three clinical-stage drug candidates in various stages of development, including:

Tamibarotene (formerly known as TM-411, TOS-80T, Am-80, and INNO-507) is an orally available, rationally designed, synthetic retinoid compound which was designed to potentially avoid toxic side effects by binding to its molecular target more selectively than all trans-retinoic acid (ATRA), the current first line treatment for APL. There is a Special Protocol Assessment (SPA) in place with the FDA for a Phase 2 registration clinical trial, known as STAR-1, which is evaluating the efficacy and safety of tamibarotene as a third-line treatment for APL. The STAR-1 trial is ongoing and currently includes seven clinical sites in the U.S.  CytRx recently reported that, of the 11 patients enrolled in the STAR-1 trial to date, 5 patients, or 45%, achieved a morphologic leukemia-free state, or MLFS.  Of those, two patients have achieved durable complete response and one has achieved morphologic leukemia-free state, or MLFS, but withdrew from the trial to receive a bone marrow transplant before the durable complete response could be confirmed. One patient achieved a complete response, but did not maintain MLFS for the required 28 days to be considered a durable complete response. Another patient achieved a durable MLFS, but did not have the necessary increases in blood cells to be considered a durable complete response. CytRx holds the North American and European rights to tamibarotene as a treatment for APL.

The FDA has granted Orphan Drug Designation for APL and Fast Track Designation for the use of tamibarotene in patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide. In addition, tamibarotene has been granted orphan medicinal product status by the European Medicines Agency for the treatment of APL.  The efficacy of orally-administered tamibarotene was demonstrated in two Phase 2 studies conducted in Japan in a total of 63 Japanese subjects with APL. The overall complete response rate in these subjects was 60%. In subjects experiencing their first relapse, the overall complete response rate was 81%.

APL is diagnosed in approximately 1,500 new patients in the United States annually. The near-term market opportunity for CytRx’s tamibarotene in refractory APL in the U.S. alone is estimated to approach $20 million per year – with the market opportunity for an expanded label including refractory, maintenance and front-line therapy increasing to $150 million in potential recurring revenue in the U.S. and Europe. There are currently no approved third-line treatment options for refractory APL patients.

FavStocks.com - CytRx Technical Breakout on Pending News (NASDAQ:CYTR)

According to the ADA, the cost of diabetes care in the United States in 2007 was more than $174 billion, including $116 billion in excess medical expenditures attributed to diabetes and $58 billion in reduced national productivity. The ADA estimates that people with diabetes, on average, have medical expenditures that are approximately 2.3 times higher than the expenditures would be in the absence of diabetes and that approximately $1 in $10 health care dollars is attributed to diabetes. A significant portion of overall diabetes care costs, approximately $7 billion according to industry sources, is attributable to costs associated with monitoring blood glucose levels, and that market segment is projected to grow substantially by 2010 as patients and their physicians seek ways to manage glucose levels more effectively.

About Echo Therapeutics, Inc.

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in acute and critical care. Echo’s non-invasive Symphony tCGM System consists of its Prelude SkinPrep System, which incorporates patented and leading-edge skin ablation control technology, and wireless transmission and proprietary transdermal biosensor technologies. Echo’s Symphony tCGM System is designed to provide both diabetes and hospital patients with a reliable, needle-free, easy-to-use, affordable and comfortable-to-wear continuous glucose monitoring device. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Clinical Pipeline

Symphonyâ„¢ tCGM System Pipeline

AzoneTSâ„¢ Pipeline

Product Information

Symphony™ tCGM System

Transdermal Continuous Glucose Monitoring (tCGM) System

Echo’s Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system designed to provide reliable, continuous blood glucose data throughout the day and night, improve patient compliance to one-point-in-time glucose testing, and achieve better overall glucose control for people with diabetes and for use in hospital critical care units.

@@Adsense@@ Investors have begun to feel a renewed sense of optimism towards the company on the eve of their recent press release. Sinobiopharma announced that 23 generic drugs for which the Company has production rights are listed in China’s National Essential Drugs List, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China.

According to the Chinese government’s healthcare reform plan, 90 percent of China’s citizens will be covered by a universal healthcare system by the year 2010. Under the plan, drugs on the National Essential Drugs List (the “List”) will be purchased by various levels of government first, then distributed to medical facilities. All drugs on the List will be covered by the basic insurance plan supported by the government. The plan also calls for medical facilities to be upgraded, which includes the construction of 30,000 new hospitals, clinics and care centers across China.

Dr. Lequn Lee Huang, Sinobiopharma President and CEO was also quick to point out that, “We expect that this new advantage in the marketplace will also enable the Company to enhance our ability to improve return on investment for shareholders in 2010.”

The news comes at an opportune time, as the company managed to post its first overall net profitable quarter since the Q2  2008. (’bout time!)

• Revenues increased to US $1,293,764 for the three months ended August 31, 2009, from US $931,203 in the corresponding period in 2008. This is an increase of 39%.
• Gross profit increased 57% to US $962,923, reflecting a 74% gross margin for the three months ended August 31, 2009.
• An overall net profit overall of US $237,167 for the three months ended August 31, 2009, marks the first time that Sinobiopharma has moved to net profitability in more than a year.

About Sinobiopharma, Inc.

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world’s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs

Economic Conditions Affecting Sinobiopharma

@@CalendarLeft@@ After three years of broad consultation, intense debate and repeated revision, the Chinese government announced in early April 2009 the long-awaited Guidelines on Deepening the Reform of Health Care System, a blueprint for health care over the next decade as well as an ambitious three-year CNY 850 billion (equivalent to 124 billion US dollars) action plan to be implemented between 2009-2011, which is on top of the CNY 4 trillion stimulus package.

With the core principle of providing the primary health care as a public service, the blueprint aims to put in place by 2020 a basic health-care system that can provide “safe, effective, convenient, and affordable” health services to all urban and rural residents.

The three-year plan will strive to cover more than 90 per cent of the population under the primary medical insurance programmes (consisting of UEMI, URBMI and NRCMS), introduce the essential medicines system, improve primary health-care facilities, provide equitable access to the basic public health-care services, and conduct pilot reforms of public hospitals. Link to the story found here

According to recent reports, economic conditions are expected to continue to boost the growth of the pharmaceutical industry in China. The health of these drug developers and manufacturers has been improving continuously for the past nine years and it’s expected to get even better since the Chinese pharmaceuticals market is forecast to become the world’s firth largest by 2010 – and the largest by 2050.

Technical Chart Analysis

After downward momentum having plagued this company for much of the past year, it seems to have consolidated around the 0.20, finding a nice support level. Throughout August, September and October the stock struggled to maintain any upward momentum it may have gained due to low volume. As we can see, this all changed on 11/16/09, when record volume of 2,911,677 came running in to shoot the stock to a 38.89% close above the opening price. The MACD and EMA have once again engaged in a golden cross formation, something which has been familiar throughout the coming months. However, this time seems different as there appears to be an explosion of volume to help support this bullish signal. 11/17/09 will play a key role, should the company finish above the 0.34 resistance, 0.43 could be the next stop in price per share. The Relative Strength Index (RSI) appears at first glance to represent an overbought stock, however, in light of the downward momentum over the past year, a major correction is due. There has been heavy short interest within the last 3 months growing well over 3,200%+, as indicated by PinkSheets.com. Expect an additional boost in share price as shorts rush to cover due to the 0.3 days left to cover, as per data provided by ShortSqueeze.com.
Disclosure: Long SNBP